Akero Therapeutics, Inc.

NasdaqGS AKRO

Akero Therapeutics, Inc. Interest Coverage Ratio for the Trailing 12 Months (TTM) ending September 30, 2024: -53.35

Akero Therapeutics, Inc. Interest Coverage Ratio is -53.35 for the Trailing 12 Months (TTM) ending September 30, 2024, a -16.84% change year over year. Interest coverage ratio assesses earnings' ability to cover interest expenses; higher ratios signal lower risk.

Akero Therapeutics, Inc. Interest Coverage Ratio for the Trailing 12 Months (TTM) ending September 30, 2023 was -45.66, a 85.78% change year over year.
Akero Therapeutics, Inc. Interest Coverage Ratio for the Trailing 12 Months (TTM) ending September 30, 2022 was -321.19.

Key data

Date	Interest Coverage Ratio	Debt to Equity Ratio	Interest Expense To Sales	Inventory Turnover Ratio

NasdaqGS: AKRO

Akero Therapeutics, Inc.

CEO	Dr. Andrew Cheng M.D., Ph.D.
IPO Date	June 20, 2019
Location	United States
Headquarters	601 Gateway Boulevard
Employees	60
Sector	Health Care
Industries Pharmaceuticals Biotechnology Clinical Trials

Description

Akero Therapeutics, Inc., a cardio-metabolic nonalcoholic steatohepatitis (NASH) company, engages in the development of medicines designed to restore metabolic balance and improve overall health. The company's lead product candidate is efruxifermin (EFX), an analog of fibroblast growth factor 21, which protects against cellular stress and regulates metabolism of lipids, carbohydrates, and proteins throughout the body. It also conducts a Phase 2a clinical trial, the BALANCED study, to evaluate EFX in the treatment of biopsy-confirmed NASH patients. The company was formerly known as Pippin Pharmaceuticals, Inc. and changed its name to Akero Therapeutics, Inc. in May 2018. Akero Therapeutics, Inc. was incorporated in 2017 and is headquartered in South San Francisco, California.

Key trends

Past 5 years